ChAd-SARS-CoV-2-S
An experimental adenoviral vector vaccine.
General information
ChAd-SARS-CoV-2-S is an experimental vaccine based on chimpanzee adenovirus-36 vector (replication-incompetent) carrying a codon optimized sequence of SARS-CoV-2 S protein as an immunogen (Hassan et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2
Viral vector Animal model In vitro Mixed substance |
B6.Cg-Tg(K18-ACE2)2Prlmn/J mice; BALB/c mice; C57BL/6J mice; Vero E6 cells; Vero-Furin cells; SARS-CoV-2 (strain 2019 n-CoV/USA_WA1/2020) | 38.64 | Upon intranasal administration, the vaccine induced anti-SARS-CoV-2 S/RBD protein IgA ang IgG neutralizing antibodies, T cell response and almost completely protected mice expressing human ACE2 receptor from SARS-CoV-2 infection. No chemokine/cytokine mRNA in lung homogenates was detected in the vaccinated mice. Intramuscular administration was not as efficient. |
Aug/19/2020 |
|
A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
Spike protein Viral vector Animal model Mixed substance |
Rhesus macaques; SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 | A single-dose vaccination induced (as assessed after 1 month) anti-Spike (IgG/IgA) antibodies, anti-RBD (IgG) antibodies, neutralizing antibodies, and T cell responses in rhesus macaques, which correlated with protection of the animals in a nasal/bronchial SARS-CoV-2 challenge. A significant reduction in lung viral loads and lung pathology compared to control was observed. |
Mar/17/2021 |
